Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
뇌전증약을 복용 중인 뇌전증 환자에서 코로나바이러스감염증-19 치료제를 사용할 때 고려사항Consideration for Coronavirus Disease 2019 Drug Treatment in Patients with Epilepsy on Antiepileptic Drugs
- Other Titles
- Consideration for Coronavirus Disease 2019 Drug Treatment in Patients with Epilepsy on Antiepileptic Drugs
- Issue Date
- May-2022
- Publisher
- 대한신경과학회
- Keywords
- COVID-19; Epilepsy; Anticonvulsants; Drug interactions
- Citation
- 대한신경과학회지, v.40, no.2, pp 121 - 126
- Pages
- 6
- Journal Title
- 대한신경과학회지
- Volume
- 40
- Number
- 2
- Start Page
- 121
- End Page
- 126
- ISSN
- 1225-7044
2288-985X
- Abstract
- Several medications are approved to treat coronavirus disease 2019 (COVID-19) in Korea including nirmatrelvir/ritonavir, remdesivir, and regdanvimab. There is potential drug-drug interaction between antiepileptic drugs (AEDs) and the medications used to treat COVID-19. Several AEDs such as phenytoin, carbamazepine, phenobarbital, and primidone are strong cytochrome P450 inducers and can inhibit the drugs used for COVID-19. Particularly, these drugs are contraindicated with nirmatrelvir/ritonavir (Paxlovid® ). There is a weaker drug-drug interaction between the AEDs and remdesivir. No significant interaction has been reported between the AEDs and molnupiravir. Pharmacokinetic interactions of the AEDs are important in effective management of COVID-19 in patients with epilepsy
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Neurology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Related Researcher
- Moon, Hye Jin
- College of Medicine (Department of Neurology)